" class="no-js "lang="en-US"> National Institute of Health (NIH) Awards Aracari Biosciences a Grant to Further Develop Proprietary Human Bone Marrow Technology That Models in Vivo Drug Responses - Medtech Alert
Friday, October 04, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
National Institute of Health (NIH) Awards Aracari Biosciences a Grant to Further Develop Proprietary Human Bone Marrow Technology That Models in Vivo Drug Responses | Pharmtech Focus|Aracari Biosciences | Pharmtech Focus

May 6 2022

National Institute of Health (NIH) Awards Aracari Biosciences a Grant to Further Develop Proprietary Human Bone Marrow Technology That Models in Vivo Drug Responses

Aracari Biosciences, Inc. announces a grant award from the National Institute of Health (NIH) to further develop Aracari’s proprietary human bone marrow technology that models in vivo drug responses.

The most common adverse drug effect on the human bone marrow is compromised production of neutrophils, which is manifested clinically as neutropenia. The Aracari human bone marrow model (“VMBM”) has the unique ability to reproduce the bone marrow microenviroment and show neutrophils exiting the bone marrow and entering the peripheral blood circulation, thereby modeling the clinical signs of neutropenia.

Using small animals to model the human bone marrow’s response to chemotherapies or other drugs is resource intensive and can be misleading due to fundamental differences in leukocyte biology between humans and rodents. For example, neutrophils normally comprise 75%-90% of the leukocyte population in human peripheral blood, but only 10%-25% in mice.

“We are very excited that the NIH recognizes the power of Aracari’s bone marrow model to predict human responses to the wide array of drugs that either inhibit or stimulate human bone marrow,” shares Steven C. George, MD, PhD, Co-founder of Aracari Biosciences.

People In This Post

Steven C. George

Steven C. George

Companies In This Post

Aracari Biosciences | Pharmtech Focus

Aracari Biosciences
  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On